查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1596241

風濕病藥物市場：依適應症、通路分類 - 全球預測 2025-2030 年

Rheumatology Therapeutics Market by Indication (Ankylosing Spondylitis, Gout, Osteoarthritis), Distribution Channel (Offline Mode, Online Stores) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年風濕病藥物市值為312.3億美元，預計到2024年將達到332.4億美元，複合年成長率為6.51%，到2030年將達到485.8億美元。

風濕病藥物市場包括旨在控制風濕性疾病（如類風濕性關節炎、紅斑性狼瘡和骨關節炎）的治療和療法。由於遺傳傾向和生活方式改變等因素，人口老化和這些疾病盛行率的增加更加強調了這一需求。應用範圍正在從DMARD和生物製藥等藥物擴展到生物相似藥和新基因療法等先進治療方法。最終使用領域包括醫院、診所和專科醫療中心，提供全面的治療途徑。關鍵的成長要素包括對有效治療方法的需求不斷增加、發展中地區醫療保健基礎設施的擴大以及創新藥物開發的持續研究。人工智慧診斷和個人化醫療等技術創新也至關重要，為具有前瞻性思維的公司探索針對個別患者需求的個人化治療解決方案提供了潛在機會。

主要市場統計
基準年[2023] 312.3億美元
預測年份 [2024] 332.4億美元
預測年份 [2030] 485.8億美元
複合年成長率（%） 6.51%

然而，市場面臨重大挑戰，包括與生物製藥相關的高成本、嚴格的法律規範以及潛在的副作用和對長期治療的抗藥性。此外，農村地區患者意識低下和疾病診斷的複雜性也阻礙了市場成長。儘管存在這些障礙，仍有許多創新途徑，特別是在專注於提高藥物療效和減少副作用的研究方面。整合巨量資料分析來預測疾病進展和治療結果也可能開啟新領域。探索現有藥物的新遞送機制有可能進一步提高療效和患者依從性。市場競爭激烈，大型製藥企業都在投資研發和策略聯盟，以擴大產品系列。為了挖掘市場潛力，公司正在推進臨床試驗，與生物技術公司合作，並制定教育計劃，以提高人們對風濕病和治療方案的認知，特別是在服務不足的地區。

市場動態：揭示快速發展的風濕病藥物市場的關鍵市場洞察

供需的動態交互作用正在改變風濕病藥物市場。了解這些不斷變化的市場動態可以幫助企業做出明智的投資決策、策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 加上老年人口的增加，類風濕性關節炎的盛行率在全球範圍內不斷增加。
    • 提供有利的報銷政策
    • 新治療藥物上市增加
  • 市場限制因素
    • RA藥物高成本
  • 市場機會
    • 診斷方法和醫療基礎設施的發展和改進
    • 傳播患者對關節炎及其預防的認知
  • 市場挑戰
    • 可能對胃壁、腎臟損傷和心臟問題產生影響

波特五力：駕馭風濕病藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解風濕病藥物市場的外部影響

外部宏觀環境因素在塑造風濕病藥物市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解風濕病治療藥物市場的競爭狀況

對風濕病藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣式風濕病藥物市場供應商的績效評估

FPNV定位矩陣是評估風濕病藥物市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議，描繪風濕病藥物市場的成功之路

風濕病藥物市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球類風濕性關節炎的發生率不斷上升，老年人口也在增加。
      • 提供優惠的退款政策
      • 增加新治療藥物的上市
    • 抑制因素
      • RA藥物高成本
    • 機會
      • 診斷和醫療基礎設施的開發和改進
      • 提高患者對關節炎及其預防的認知
    • 任務
      • 對胃壁的影響、可能的腎臟損傷和心臟問題
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 類風濕性關節炎藥物市場（依適應症）

  • 僵直性脊椎炎
  • 痛風
  • 骨關節炎
  • 乾癬性關節炎
  • 類風濕性關節炎

第7章風濕病藥物市場：依通路分類

  • 離線模式
  • 網路商店

第8章 北美和南美風濕病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區風濕病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲風濕病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie, Inc.
  • Amgen, Inc.
  • AstraZeneca Plc
  • Bayer AG
  • Beckman Coulter, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Qiagen NV
  • Regeneron Pharmaceuticals, Inc.
  • Rigel Pharmaceuticals, Inc.
  • Sanofi SA
  • Thermo Fisher Scientific, Inc.
Product Code: MRR-437896AA372B

The Rheumatology Therapeutics Market was valued at USD 31.23 billion in 2023, expected to reach USD 33.24 billion in 2024, and is projected to grow at a CAGR of 6.51%, to USD 48.58 billion by 2030.

The rheumatology therapeutics market encompasses treatments and therapies aimed at managing rheumatic diseases, including rheumatoid arthritis, lupus, and osteoarthritis. The necessity is underscored by an aging population and increasing prevalence of these diseases, amplified by factors like genetic predisposition and lifestyle changes. The application scope extends from pharmaceuticals, such as DMARDs and biologics, to advanced therapies like biosimilars and emerging gene therapies. End-use sectors include hospitals, clinics, and specialty care centers, providing comprehensive treatment pathways. Key growth factors include the rising demand for effective treatment modalities, expansion of healthcare infrastructure in developing regions, and ongoing research leading to innovative drug development. Technological innovations like AI-driven diagnostics and personalized medicine are also pivotal, offering potential opportunities for forward-thinking companies to explore personalized therapeutic solutions catering to individual patient needs.

KEY MARKET STATISTICS
Base Year [2023] USD 31.23 billion
Estimated Year [2024] USD 33.24 billion
Forecast Year [2030] USD 48.58 billion
CAGR (%) 6.51%

Nevertheless, the market faces significant challenges, such as high costs associated with biologic drugs, stringent regulatory frameworks, and potential side effects or resistance to long-term treatment. Additionally, limited patient awareness in rural areas and the complexity of disease diagnosis impede market growth. Despite these hurdles, there are ample avenues for innovation, particularly in research focused on enhancing drug efficacy and reducing adverse effects. Integrating big data analytics to predict disease progression and treatment outcomes can also open new frontiers. Exploring novel delivery mechanisms for existing drugs may further bolster efficacy and patient compliance. The nature of the market is highly competitive, with major pharmaceutical players investing in R&D and strategic partnerships aimed at expanding their product portfolios. To capitalize on market potential, companies should focus on advancing clinical trials, forming collaborations with biotech firms, and establishing educational initiatives to raise awareness about rheumatic diseases and treatment options, particularly in underserved regions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Rheumatology Therapeutics Market

The Rheumatology Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing incidence of rheumatoid arthritis globally coupled with increasing geriatric population
    • Availability of favorable reimbursement policies
    • Increasing launch of novel therapeutic agents
  • Market Restraints
    • High cost of RA therapeutics
  • Market Opportunities
    • Developments and improvements in diagnostics and healthcare infrastructure
    • Widespread awareness on arthritis and its prevention among patients
  • Market Challenges
    • Probable impact on lining of stomach, kidney damage, and heart issues

Porter's Five Forces: A Strategic Tool for Navigating the Rheumatology Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Rheumatology Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Rheumatology Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Rheumatology Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Rheumatology Therapeutics Market

A detailed market share analysis in the Rheumatology Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Rheumatology Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Rheumatology Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Rheumatology Therapeutics Market

A strategic analysis of the Rheumatology Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Rheumatology Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., Amgen, Inc., AstraZeneca Plc, Bayer AG, Beckman Coulter, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Qiagen NV, Regeneron Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Sanofi SA, and Thermo Fisher Scientific, Inc..

Market Segmentation & Coverage

This research report categorizes the Rheumatology Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Indication, market is studied across Ankylosing Spondylitis, Gout, Osteoarthritis, Psoriatic Arthritis, and Rheumatoid Arthritis.
  • Based on Distribution Channel, market is studied across Offline Mode and Online Stores.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing incidence of rheumatoid arthritis globally coupled with increasing geriatric population
      • 5.1.1.2. Availability of favorable reimbursement policies
      • 5.1.1.3. Increasing launch of novel therapeutic agents
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of RA therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Developments and improvements in diagnostics and healthcare infrastructure
      • 5.1.3.2. Widespread awareness on arthritis and its prevention among patients
    • 5.1.4. Challenges
      • 5.1.4.1. Probable impact on lining of stomach, kidney damage, and heart issues
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Rheumatology Therapeutics Market, by Indication

  • 6.1. Introduction
  • 6.2. Ankylosing Spondylitis
  • 6.3. Gout
  • 6.4. Osteoarthritis
  • 6.5. Psoriatic Arthritis
  • 6.6. Rheumatoid Arthritis

7. Rheumatology Therapeutics Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Offline Mode
  • 7.3. Online Stores

8. Americas Rheumatology Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Rheumatology Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Rheumatology Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie, Inc.
  • 2. Amgen, Inc.
  • 3. AstraZeneca Plc
  • 4. Bayer AG
  • 5. Beckman Coulter, Inc.
  • 6. Boehringer Ingelheim GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Eli Lilly and Company
  • 9. F. Hoffmann-La Roche AG
  • 10. Gilead Sciences, Inc.
  • 11. Johnson & Johnson Services, Inc.
  • 12. Merck & Co., Inc.
  • 13. Novartis International AG
  • 14. Pfizer, Inc.
  • 15. Qiagen NV
  • 16. Regeneron Pharmaceuticals, Inc.
  • 17. Rigel Pharmaceuticals, Inc.
  • 18. Sanofi SA
  • 19. Thermo Fisher Scientific, Inc.

LIST OF FIGURES

  • FIGURE 1. RHEUMATOLOGY THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. RHEUMATOLOGY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. RHEUMATOLOGY THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY GOUT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OSTEOARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY OFFLINE MODE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY ONLINE STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 25. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 27. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 30. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. TAIWAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. VIETNAM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 60. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM RHEUMATOLOGY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. RHEUMATOLOGY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 103. RHEUMATOLOGY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023